CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY Director | Gift | −724,637 | 0 | ||
| 2026-05-09 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +22,000 | 22,000 | ||
| 2025-12-22 | FAIRBAIRN EMILY Director | Grant or award | +724,637 | $1.38 | $1000K | 724,637 |
| 2025-05-08 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +63,150 | 63,150 | ||
| 2024-12-19 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +31,559 | 31,559 | ||
| 2024-10-04 | FAIRBAIRN EMILY Director | Purchase · Series C Warrants (right to buy) | +3,038,743 | 3,038,743 | ||
| 2024-10-04 | FAIRBAIRN EMILY Director | Purchase · Pre-Funded Warrants (right to buy) | +3,038,743 | 3,038,743 | ||
| 2024-06-12 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +33,650 | 33,650 | ||
| 2023-07-28 | FAIRBAIRN EMILY Director | Other disposition | −4,111,958 | 0 | ||
| 2023-06-15 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2022-08-16 | FAIRBAIRN EMILY Director | Purchase | +789,473 | $1.90 | $1.5M | 4,111,958 |
| 2022-06-01 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion | +83,124 | 91,336 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion | +27,706 | 27,706 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion | +3,222,485 | 3,222,485 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Purchase | +100,000 | $10.00 | $1.0M | 3,322,485 |
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion · Series A Preferred Stock | −75,588 | 0 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion · Series A Preferred Stock | −25,195 | 0 | ||
| 2021-08-03 | FAIRBAIRN EMILY Director | Conversion · Series A Preferred Stock | −2,930,332 | 0 |
Page 1 of 2 · 21 trades